1. Frieder A, Fersh M, Hainline R, et al. Pharmacotherapy of postpartum depression: current approaches and novel drug development. CNS Drugs. 2019;33(3):265–82.
2. Rubin R. A fast-acting pill received approval for postpartum depression—is it a game changer? JAMA. 2023. https://doi.org/10.1001/jama.2023.16499.
3. Gunduz-Bruce H, Takahashi K, Huang MY. Development of neuroactive steroids for the treatment of postpartum depression. J Neuroendocrinol. 2022;34(e13019):1–10.
4. US Food & Drug Administration. FDA approves first oral treatment for postpartum depression [media release]. 4 Aug 2023. https://www.fda.gov/news-events/press-announcements/fda-approves-first-oral-treatment-postpartum-depression.
5. Sage Therapeutics. FDA approves ZURZUVAE™ (zuranolone), the first and only oral treatment approved for women with postpartum depression, and issues a complete response letter for major depressive disorder [media release]. 4 Aug 2023. https://investor.sagerx.com/news-releases/news-release-details/fda-approves-zurzuvaetm-zuranolone-first-and-only-oral-treatment.